EDIT Editas Medicine Inc.

28.08
-0.27  -1%
Previous Close 28.35
Open 27.31
Price To Book 6.87
Market Cap 1,440,564,490
Shares 51,302,885
Volume 411,496
Short Ratio
Av. Daily Volume 984,652
Stock charts supplied by TradingView

NewsSee all news

  1. Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

    Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE

  2. Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

    CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a

  3. Editas Medicine Reports Inducement Grants to New Chief Financial Officer

    CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Chief Financial

  4. Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

    Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Editas

  5. Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 dosing to commence early 2020.
AGN-151587 (EDIT-101)
Leber Congenital Amaurosis type 10 (LCA10).

Latest News

  1. Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

    Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE

  2. Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

    CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a

  3. Editas Medicine Reports Inducement Grants to New Chief Financial Officer

    CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Chief Financial

  4. Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

    Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Editas

  5. Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer

  6. Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

    CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a

  7. Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new

  8. Editas Medicine Announces Third Quarter 2019 Results and Update

    Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief Medical Officer EDIT-101 (AGN-151587) for

  9. Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

    The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells Editas Medicine to receive a $70 million payment and may be eligible for future milestone and

  10. Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update

    CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 12, 2019,

  11. Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer

    CAMBRIDGE, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company's Chief Medical Officer,

  12. Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

    CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences

  13. Editas Medicine to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor

  14. Editas Medicine to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in the following investor conferences in